Fox Run Management, L.L.C. Syndax Pharmaceuticals Inc Transaction History
Fox Run Management, L.L.C.
- $526 Million
- Q4 2024
A detailed history of Fox Run Management, L.L.C. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 16,355 shares of SNDX stock, worth $249,904. This represents 0.04% of its overall portfolio holdings.
Number of Shares
16,355
Previous 29,956
45.4%
Holding current value
$249,904
Previous $576,000
62.5%
% of portfolio
0.04%
Previous 0.13%
Shares
5 transactions
Others Institutions Holding SNDX
# of Institutions
233Shares Held
96.9MCall Options Held
1.39MPut Options Held
543K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$130 Million7.14% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$121 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.95MShares$90.9 Million0.01% of portfolio
-
Morgan Stanley New York, NY5.31MShares$81.2 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.88MShares$74.6 Million0.0% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $864M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...